{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T19:14:42Z","timestamp":1795029282414,"version":"4.10.2"},"reference-count":128,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T00:00:00Z","timestamp":1728432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T00:00:00Z","timestamp":1728432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"DOI":"10.1186\/s12883-024-03857-z","type":"journal-article","created":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T01:01:51Z","timestamp":1728435711000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Improvements in clinical signs and symptoms of Parkinson\u2019s disease using photobiomodulation: a five-year follow-up"],"prefix":"10.1186","volume":"24","author":[{"given":"Ann","family":"Liebert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Bicknell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E-Liisa","family":"Laakso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Tilley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillian","family":"Heller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hosen","family":"Kiat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey","family":"Herkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,9]]},"reference":[{"key":"3857_CR1","doi-asserted-by":"publisher","first-page":"776847","DOI":"10.3389\/fpubh.2021.776847","volume":"9","author":"Z Ou","year":"2021","unstructured":"Ou Z, Pan J, Tang S, Duan D, Yu D, Nong H, et al. Global trends in the incidence, prevalence, and years lived with disability of Parkinson\u2019s disease in 204 countries\/territories from 1990 to 2019. Front Public Health. 2021;9:776847.","journal-title":"Front Public Health"},{"key":"3857_CR2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.pneurobio.2018.09.003","volume":"177","author":"A Gr\u00fcnewald","year":"2019","unstructured":"Gr\u00fcnewald A, Kumar KR, Sue CM. New insights into the complex role of mitochondria in Parkinson\u2019s disease. Prog Neurobiol. 2019;177:73\u201393.","journal-title":"Prog Neurobiol"},{"issue":"2","key":"3857_CR3","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1002\/mds.27602","volume":"34","author":"K Seppi","year":"2019","unstructured":"Seppi K, Ray Chaudhuri K, Coelho M, Fox SH, Katzenschlager R, Perez Lloret S, et al. Update on treatments for nonmotor symptoms of Parkinson\u2019s disease\u2014an evidence-based medicine review. Mov Disord. 2019;34(2):180\u201398.","journal-title":"Mov Disord"},{"issue":"8","key":"3857_CR4","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1002\/mds.27372","volume":"33","author":"SH Fox","year":"2018","unstructured":"Fox SH, Katzenschlager R, Lim SY, Barton B, de Bie RMA, Seppi K, et al. International Parkinson and movement disorder society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson\u2019s disease. Mov Disord. 2018;33(8):1248\u201366.","journal-title":"Mov Disord"},{"issue":"3","key":"3857_CR5","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.3233\/JPD-201932","volume":"10","author":"MM Lewis","year":"2020","unstructured":"Lewis MM, Harkins E, Lee EY, Stetter C, Snyder B, Corson T, et al. Clinical progression of Parkinson\u2019s Disease: insights from the NINDS Common Data Elements. J Parkinsons Dis. 2020;10(3):1075\u201385.","journal-title":"J Parkinsons Dis"},{"issue":"10423","key":"3857_CR6","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S0140-6736(23)01478-2","volume":"403","author":"HR Morris","year":"2024","unstructured":"Morris HR, Spillantini MG, Sue CM, Williams-Gray CH. The pathogenesis of Parkinson\u2019s disease. Lancet. 2024;403(10423):293\u2013304.","journal-title":"Lancet"},{"issue":"Suppl 2","key":"3857_CR7","first-page":"S50","volume":"10","author":"A Antonini","year":"2023","unstructured":"Antonini A, Emmi A, Campagnolo M. Beyond the dopaminergic system: lessons learned from levodopa resistant symptoms in Parkinson\u2019s disease. Mov Disorders Clin Pract. 2023;10(Suppl 2):S50.","journal-title":"Mov Disorders Clin Pract"},{"issue":"1","key":"3857_CR8","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1001\/jama.2008.929","volume":"301","author":"FM Weaver","year":"2009","unstructured":"Weaver FM, Follett K, Stern M, Hur K, Harris C, Marks WJ Jr., et al. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA. 2009;301(1):63\u201373.","journal-title":"JAMA"},{"key":"3857_CR9","doi-asserted-by":"crossref","unstructured":"Crotty GF, Schwarzschild MA. Chasing Protection in Parkinson\u2019s Disease: does Exercise reduce risk and progression? Front Aging Neurosci. 2020;12.","DOI":"10.3389\/fnagi.2020.00186"},{"key":"3857_CR10","doi-asserted-by":"crossref","unstructured":"Fujikawa J, Morigaki R, Yamamoto N, Oda T, Nakanishi H, Izumi Y et al. Therapeutic devices for motor symptoms in Parkinson\u2019s Disease: current progress and a systematic review of recent randomized controlled trials. Front Aging Neurosci. 2022;14.","DOI":"10.3389\/fnagi.2022.807909"},{"issue":"2","key":"3857_CR11","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/php.12864","volume":"94","author":"MR Hamblin","year":"2018","unstructured":"Hamblin MR. Mechanisms and mitochondrial Redox Signaling in Photobiomodulation. Photochem Photobiol. 2018;94(2):199\u2013212.","journal-title":"Photochem Photobiol"},{"key":"3857_CR12","doi-asserted-by":"publisher","first-page":"111916","DOI":"10.1016\/j.jphotobiol.2020.111916","volume":"208","author":"P Benson","year":"2020","unstructured":"Benson P, Kim JY, Riveros C, Camp A, Johnstone DM. Elucidating the time course of the transcriptomic response to photobiomodulation through gene co-expression analysis. J Photochem Photobiol B. 2020;208:111916.","journal-title":"J Photochem Photobiol B"},{"issue":"1","key":"3857_CR13","doi-asserted-by":"publisher","first-page":"10581","DOI":"10.1038\/srep10581","volume":"5","author":"I Khan","year":"2015","unstructured":"Khan I, Tang E, Arany P. Molecular pathway of near-infrared laser phototoxicity involves ATF-4 orchestrated ER stress. Sci Rep. 2015;5(1):10581.","journal-title":"Sci Rep"},{"issue":"10","key":"3857_CR14","doi-asserted-by":"publisher","first-page":"3081","DOI":"10.1007\/s00221-017-5048-7","volume":"235","author":"C Moro","year":"2017","unstructured":"Moro C, Torres N, Arvanitakis K, Cullen K, Chabrol C, Agay D, et al. No evidence for toxicity after long-term photobiomodulation in normal non-human primates. Exp Brain Res. 2017;235(10):3081\u201392.","journal-title":"Exp Brain Res"},{"issue":"10","key":"3857_CR15","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1089\/photob.2019.4678","volume":"37","author":"P Cassano","year":"2019","unstructured":"Cassano P, Caldieraro MA, Norton R, Mischoulon D, Trinh N-H, Nyer M, et al. Reported Side effects, Weight and Blood pressure, after repeated Sessions of Transcranial Photobiomodulation. Photobiomodulation Photomed Laser Surg. 2019;37(10):651\u20136.","journal-title":"Photobiomodulation Photomed Laser Surg"},{"issue":"3","key":"3857_CR16","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3934\/biophy.2017.3.337","volume":"4","author":"MR Hamblin","year":"2017","unstructured":"Hamblin MR. Mechanisms and applications of the anti-inflammatory effects of photobiomodulation. AIMS Biophys. 2017;4(3):337\u201361.","journal-title":"AIMS Biophys"},{"issue":"6","key":"3857_CR17","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.3390\/jcm9061724","volume":"9","author":"C Dompe","year":"2020","unstructured":"Dompe C, Moncrieff L, Matys J, Grzech-Le\u015bniak K, Kocherova I, Bryja A, et al. Photobiomodulation-underlying mechanism and clinical applications. J Clin Med. 2020;9(6):1724.","journal-title":"J Clin Med"},{"key":"3857_CR18","doi-asserted-by":"crossref","unstructured":"Shaikh-Kader A, Houreld NN, editors. Photobiomodulation, cells of connective tissue and repair processes: a look at. Vivo and in Vitro studies on Bone, Cartilage and Tendon cells. Photonics: MDPI; 2022.","DOI":"10.3390\/photonics9090618"},{"issue":"18","key":"3857_CR19","doi-asserted-by":"publisher","first-page":"14293","DOI":"10.3390\/ijms241814293","volume":"24","author":"R Zhang","year":"2023","unstructured":"Zhang R, Qu J. The mechanisms and efficacy of photobiomodulation therapy for arthritis: a comprehensive review. Int J Mol Sci. 2023;24(18):14293.","journal-title":"Int J Mol Sci"},{"issue":"19","key":"3857_CR20","doi-asserted-by":"publisher","first-page":"4423","DOI":"10.1002\/cncr.33100","volume":"126","author":"S Elad","year":"2020","unstructured":"Elad S, Cheng KKF, Lalla RV, Yarom N, Hong C, Logan RM, et al. MASCC\/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer. 2020;126(19):4423\u201331.","journal-title":"Cancer"},{"issue":"6","key":"3857_CR21","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1042\/BIO03806024","volume":"38","author":"MR Hamblin","year":"2016","unstructured":"Hamblin MR. Photobiomodulation and the brain\u2013has the light dawned? Biochemist. 2016;38(6):24\u20138.","journal-title":"Biochemist"},{"issue":"6","key":"3857_CR22","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1007\/s10103-019-02898-y","volume":"35","author":"HL Casalechi","year":"2020","unstructured":"Casalechi HL, Dumont AJL, Ferreira LAB, de Paiva PRV, Machado CSM, de Carvalho PTC, et al. Acute effects of photobiomodulation therapy and magnetic field on functional mobility in stroke survivors: a randomized, sham-controlled, triple-blind, crossover, clinical trial. Lasers Med Sci. 2020;35(6):1253\u201362.","journal-title":"Lasers Med Sci"},{"issue":"11","key":"3857_CR23","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1089\/neu.2013.3244","volume":"31","author":"MA Naeser","year":"2014","unstructured":"Naeser MA, Zafonte R, Krengel MH, Martin PI, Frazier J, Hamblin MR, et al. Significant improvements in cognitive performance post-transcranial, red\/near-infrared light-emitting diode treatments in chronic, mild traumatic brain injury: open-protocol study. J Neurotrauma. 2014;31(11):1008\u201317.","journal-title":"J Neurotrauma"},{"key":"3857_CR24","doi-asserted-by":"crossref","unstructured":"Lamartiniere R, Bergeron R, Aung-Din R, Bennett M, Stephan W, Banas L. Chapter 42 - photobiomodulation treatment for brain disorders: posttraumatic stress disorder (PTSD) and dementia. In: Hamblin MR, Huang Y-Y, editors. Photobiomodulation in the brain. Academic; 2019. pp. 589\u201397.","DOI":"10.1016\/B978-0-12-815305-5.00042-7"},{"key":"3857_CR25","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/1744-9081-5-46","volume":"5","author":"F Schiffer","year":"2009","unstructured":"Schiffer F, Johnston AL, Ravichandran CT, Polcari A, Teicher MH, Webb RH, et al. Psychological benefits 2 and 4 weeks after a single treatment with Near Infrared Light to the forehead: a pilot study of 10 patients with major depression and anxiety. Behaviural Brain Function. 2009;5:46.","journal-title":"Behaviural Brain Function"},{"issue":"8","key":"3857_CR26","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1089\/pho.2016.4227","volume":"35","author":"AE Saltmarche","year":"2017","unstructured":"Saltmarche AE, Naeser MA, Ho KF, Hamblin MR, Lim L. Significant improvement in cognition in mild to moderately severe dementia cases treated with transcranial plus intranasal photobiomodulation: case series report. Photomed Laser Surg. 2017;35(8):432\u201341.","journal-title":"Photomed Laser Surg"},{"issue":"1","key":"3857_CR27","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/cne.22207","volume":"518","author":"V Shaw","year":"2010","unstructured":"Shaw V, Ashkan K, Benabid A, Stone J, Baker G, Mitrofanis J. Neuroprotection of midbrain dopaminergic cell in MPTP-treated mice after near-infrared light treatment. J Comp Neurol. 2010;518(1):25\u201340.","journal-title":"J Comp Neurol"},{"issue":"1","key":"3857_CR28","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/alzrt232","volume":"6","author":"S Purushothuman","year":"2014","unstructured":"Purushothuman S, Johnstone D, Nandasena C, Mitrofanis J, Stone J. Photobiomodulation with near infrared light mitigates Alzheimer\u2019s disease-related pathology in cerebral cortex - evidence from two transgenic mouse models. Alzheimers Res Ther. 2014;6(1):2.","journal-title":"Alzheimers Res Ther"},{"issue":"4","key":"3857_CR29","doi-asserted-by":"publisher","first-page":"574","DOI":"10.4103\/1673-5374.205092","volume":"12","author":"J Mitrofanis","year":"2017","unstructured":"Mitrofanis J. Why and how does light therapy offer neuroprotection in Parkinson\u2019s disease? Neural Regeneration Res. 2017;12(4):574.","journal-title":"Neural Regeneration Res"},{"key":"3857_CR30","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.arr.2017.05.005","volume":"37","author":"B Kim","year":"2017","unstructured":"Kim B, Brandli A, Mitrofanis J, Stone J, Purushothuman S, Johnstone DM. Remote tissue conditioning - an emerging approach for inducing body-wide protection against diseases of ageing. Ageing Res Rev. 2017;37:69\u201378.","journal-title":"Ageing Res Rev"},{"key":"3857_CR31","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.neuroscience.2018.12.050","volume":"400","author":"V Ganeshan","year":"2019","unstructured":"Ganeshan V, Skladnev NV, Kim JY, Mitrofanis J, Stone J, Johnstone DM. Pre-conditioning with remote photobiomodulation modulates the brain transcriptome and protects against MPTP insult in mice. Neuroscience. 2019;400:85\u201397.","journal-title":"Neuroscience"},{"issue":"3","key":"3857_CR32","doi-asserted-by":"publisher","first-page":"349","DOI":"10.4103\/1673-5374.153673","volume":"10","author":"DM Johnstone","year":"2015","unstructured":"Johnstone DM, Mitrofanis J, Stone J. Targeting the body to protect the brain: inducing neuroprotection with remotely-applied near infrared light. Neural Regen Res. 2015;10(3):349\u201351.","journal-title":"Neural Regen Res"},{"issue":"12","key":"3857_CR33","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.4103\/1673-5374.262573","volume":"14","author":"LC Gordon","year":"2019","unstructured":"Gordon LC, Johnstone DM. Remote photobiomodulation: an emerging strategy for neuroprotection. Neural Regeneration Res. 2019;14(12):2086.","journal-title":"Neural Regeneration Res"},{"key":"3857_CR34","unstructured":"Stone J, Johnstone D, Mitrofanis J, editors. The helmet experiment in Parkinson\u2019s disease: an observation of the mechanism of neuroprotection by near infra-red light. 9th WALT Congress (Gold Coast, QLD); 2013."},{"issue":"1","key":"3857_CR35","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1186\/s12883-021-02248-y","volume":"21","author":"A Liebert","year":"2021","unstructured":"Liebert A, Bicknell B, Laakso EL, Heller G, Jalilitabaei P, Tilley S, et al. Improvements in clinical signs of Parkinson\u2019s disease using photobiomodulation: a prospective proof-of-concept study. BMC Neurol. 2021;21(1):256.","journal-title":"BMC Neurol"},{"key":"3857_CR36","doi-asserted-by":"crossref","unstructured":"Liebert A, Bicknell B, Laakso E-L, Tilley S, Pang V, Heller G et al. Improvements in the clinical signs of Parkinson\u2019s disease using photobiomodulation: a 3-year follow-up case series. Med Res Archives. 2023;11(3).","DOI":"10.18103\/mra.v11i3.3690"},{"issue":"11","key":"3857_CR37","doi-asserted-by":"publisher","first-page":"9577","DOI":"10.3390\/ijms24119577","volume":"24","author":"B Bicknell","year":"2023","unstructured":"Bicknell B, Liebert A, Borody T, Herkes G, McLachlan C, Kiat H. Neurodegenerative and neurodevelopmental diseases and the Gut-Brain Axis: the potential of therapeutic targeting of the Microbiome. Int J Mol Sci. 2023;24(11):9577.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"3857_CR38","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1111\/ejn.15973","volume":"57","author":"LC Gordon","year":"2023","unstructured":"Gordon LC, Martin KL, Torres N, Benabid AL, Mitrofanis J, Stone J, et al. Remote photobiomodulation targeted at the abdomen or legs provides effective neuroprotection against parkinsonian MPTP insult. Eur J Neurosci. 2023;57(9):1611\u201324.","journal-title":"Eur J Neurosci"},{"issue":"1","key":"3857_CR39","first-page":"100173","volume":"4","author":"B Joo","year":"2022","unstructured":"Joo B, Marquez JL, Osmotherly PG. Ten-second Tandem Stance Test: a potential Tool to assist walking aid prescription and Falls Risk in Balance impaired individuals. Arch Rehabil Res Clin Transl. 2022;4(1):100173.","journal-title":"Arch Rehabil Res Clin Transl"},{"issue":"6","key":"3857_CR40","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.amepre.2022.07.002","volume":"63","author":"JM Blodgett","year":"2022","unstructured":"Blodgett JM, Hardy R, Davis D, Peeters G, Kuh D, Cooper R. One-Legged Balance performance and fall risk in Mid and later life: longitudinal evidence from a British birth cohort. Am J Prev Med. 2022;63(6):997\u20131006.","journal-title":"Am J Prev Med"},{"issue":"9","key":"3857_CR41","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1093\/ptj\/80.9.896","volume":"80","author":"A Shumway-Cook","year":"2000","unstructured":"Shumway-Cook A, Brauer S, Woollacott M. Predicting the Probability for Falls in Community-Dwelling older adults using the timed Up & Go Test. Phys Ther. 2000;80(9):896\u2013903.","journal-title":"Phys Ther"},{"key":"3857_CR42","doi-asserted-by":"crossref","unstructured":"Lang JT, Kassan TO, Devaney LL, Colon-Semenza C, Joseph MF. Test-Retest Reliability and Minimal Detectable Change for the 10-Meter Walk Test in Older Adults With Parkinson\u2019s disease. J Geriatr Phys Ther. 2016;39(4).","DOI":"10.1519\/JPT.0000000000000068"},{"key":"3857_CR43","doi-asserted-by":"publisher","first-page":"257","DOI":"10.3138\/ptc.48.4.257","volume":"47","author":"K Hill","year":"1996","unstructured":"Hill K, Bernhardt J, McGann A, Maltese D, Berkovits D. A new test of dynamic standing balance for stroke patients: reliability, validity, and quantitative clinical tests. Physiotherapy Can. 1996;47:257\u201362.","journal-title":"Physiotherapy Can"},{"issue":"S3","key":"3857_CR44","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1002\/mds.870131315","volume":"13","author":"SL Pullman","year":"1998","unstructured":"Pullman SL. Spiral analysis: a new technique for measuring Tremor with a Digitizing Tablet. Mov Disord. 1998;13(S3):85\u20139.","journal-title":"Mov Disord"},{"issue":"6","key":"3857_CR45","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1093\/ptj\/78.6.577","volume":"78","author":"F Smithson","year":"1998","unstructured":"Smithson F, Morris ME, Iansek R. Performance on clinical tests of balance in Parkinson\u2019s Disease. Phys Ther. 1998;78(6):577\u201392.","journal-title":"Phys Ther"},{"issue":"10","key":"3857_CR46","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.2522\/ptj.20110283","volume":"92","author":"ES Hile","year":"2012","unstructured":"Hile ES, Brach JS, Perera S, Wert DM, VanSwearingen JM, Studenski SA. Interpreting the need for initial support to perform tandem stance tests of balance. Phys Ther. 2012;92(10):1316\u201328.","journal-title":"Phys Ther"},{"issue":"3","key":"3857_CR47","doi-asserted-by":"publisher","first-page":"338","DOI":"10.2522\/ptj.20090163","volume":"90","author":"SW Muir","year":"2010","unstructured":"Muir SW, Berg K, Chesworth B, Klar N, Speechley M. Balance impairment as a risk factor for falls in community-dwelling older adults who are high functioning: a prospective study. Phys Ther. 2010;90(3):338\u201347.","journal-title":"Phys Ther"},{"issue":"7","key":"3857_CR48","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1002\/mds.22017","volume":"23","author":"DJ Gill","year":"2008","unstructured":"Gill DJ, Freshman A, Blender JA, Ravina B. The Montreal cognitive assessment as a screening tool for cognitive impairment in Parkinson\u2019s disease. Mov Disord. 2008;23(7):1043\u20136.","journal-title":"Mov Disord"},{"issue":"1","key":"3857_CR49","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1007\/PL00007730","volume":"245","author":"V Peto","year":"1998","unstructured":"Peto V, Jenkinson C, Fitzpatrick R. PDQ-39: a review of the development, validation and application of a Parkinson\u2019s disease quality of life questionnaire and its associated measures. J Neurol. 1998;245(1):S10\u20134.","journal-title":"J Neurol"},{"issue":"6","key":"3857_CR50","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/jnnp.73.6.629","volume":"73","author":"KR Chaudhuri","year":"2002","unstructured":"Chaudhuri KR, Pal S, DiMarco A, Whately-Smith C, Bridgman K, Mathew R, et al. The Parkinson\u2019s disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry. 2002;73(6):629\u201335.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"3857_CR51","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/mdc3.12553","volume":"5","author":"SK Holden","year":"2018","unstructured":"Holden SK, Finseth T, Sillau SH, Berman BD. Progression of MDS-UPDRS scores over five years in De Novo Parkinson Disease from the Parkinson\u2019s progression markers Initiative Cohort. Mov Disorders Clin Pract. 2018;5(1):47\u201353.","journal-title":"Mov Disorders Clin Pract"},{"key":"3857_CR52","doi-asserted-by":"crossref","unstructured":"Foltynie T, Athauda D. Chapter 13 - Repurposing anti-diabetic drugs for the treatment of Parkinson\u2019s disease: Rationale and clinical experience. In: Bj\u00f6rklund A, Cenci MA, editors. Progress in Brain Research. Volume 252. Elsevier; 2020. pp. 493\u2013523.","DOI":"10.1016\/bs.pbr.2019.10.008"},{"issue":"7","key":"3857_CR53","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/jp.2015.5","volume":"35","author":"AL Kent","year":"2015","unstructured":"Kent AL, Broom M, Parr V, Essex RW, Abdel-Latif ME, Dahlstrom JE, et al. A safety and feasibility study of the use of 670 nm red light in premature neonates. J Perinatol. 2015;35(7):493\u20136.","journal-title":"J Perinatol"},{"issue":"22","key":"3857_CR54","doi-asserted-by":"publisher","first-page":"8279","DOI":"10.1002\/cam4.3582","volume":"9","author":"RJ Bensadoun","year":"2020","unstructured":"Bensadoun RJ, Epstein JB, Nair RG, Barasch A, Raber-Durlacher JE, Migliorati C, et al. Safety and efficacy of photobiomodulation therapy in oncology: a systematic review. Cancer Med. 2020;9(22):8279\u2013300.","journal-title":"Cancer Med"},{"issue":"8","key":"3857_CR55","doi-asserted-by":"publisher","first-page":"507","DOI":"10.3390\/photonics9080507","volume":"9","author":"P Cassano","year":"2022","unstructured":"Cassano P, Norton R, Caldieraro MA, Vahedifard F, Vizcaino F, McEachern KM, et al. Tolerability and safety of transcranial photobiomodulation for mood and anxiety disorders. Photonics. 2022;9(8):507.","journal-title":"Photonics"},{"key":"3857_CR56","doi-asserted-by":"crossref","unstructured":"Herkes G, McGee C, Liebert A, Bicknell B, Isaac A, Kiat H et al. A novel transcranial photobiomodulation device to address motor signs of Parkinson\u2019s disease: a parallel randomised feasibility study. EClinicalMedicine. 2023;66.","DOI":"10.1016\/j.eclinm.2023.102338"},{"issue":"3","key":"3857_CR57","doi-asserted-by":"publisher","first-page":"367","DOI":"10.2169\/internalmedicine.4836-20","volume":"60","author":"C Ishida","year":"2021","unstructured":"Ishida C, Takahashi K, Kato-Motozaki Y, Tagami A, Komai K. Effectiveness of Levodopa in patients with multiple system atrophy and Associated Clinicopathological features. Intern Med. 2021;60(3):367\u201372.","journal-title":"Intern Med"},{"issue":"5","key":"3857_CR58","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s12311-022-01453-w","volume":"22","author":"I Stankovic","year":"2023","unstructured":"Stankovic I, Fanciulli A, Sidoroff V, Wenning GK. A review on the clinical diagnosis of multiple system atrophy. Cerebellum. 2023;22(5):825\u201339.","journal-title":"Cerebellum"},{"issue":"8","key":"3857_CR59","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1001\/archgenpsychiatry.2010.88","volume":"67","author":"SC Lidstone","year":"2010","unstructured":"Lidstone SC, Schulzer M, Dinelle K, Mak E, Sossi V, Ruth TJ, et al. Effects of expectation on placebo-induced dopamine release in Parkinson disease. Arch Gen Psychiatry. 2010;67(8):857\u201365.","journal-title":"Arch Gen Psychiatry"},{"issue":"8","key":"3857_CR60","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1002\/mds.27438","volume":"33","author":"A Quattrone","year":"2018","unstructured":"Quattrone A, Barbagallo G, Cerasa A, Stoessl AJ. Neurobiology of placebo effect in Parkinson\u2019s disease: what we have learned and where we are going. Mov Disord. 2018;33(8):1213\u201327.","journal-title":"Mov Disord"},{"issue":"4","key":"3857_CR61","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.3233\/JAD-210170","volume":"83","author":"J Bullock-Saxton","year":"2021","unstructured":"Bullock-Saxton J, Lehn A, Laakso E. Exploring the effect of combined transcranial and intra-oral photobiomodulation therapy over a four-week period on physical and cognitive outcome measures for people with Parkinson\u2019s disease: a randomized double-blind placebo-controlled pilot study. J Alzheimers Dis. 2021;83(4):1499\u2013512.","journal-title":"J Alzheimers Dis"},{"issue":"8","key":"3857_CR62","doi-asserted-by":"publisher","first-page":"2846","DOI":"10.3390\/jcm12082846","volume":"12","author":"C McGee","year":"2023","unstructured":"McGee C, Liebert A, Bicknell B, Pang V, Isaac V, McLachlan CS, et al. A randomized placebo-controlled study of a Transcranial Photobiomodulation Helmet in Parkinson\u2019s Disease: post-hoc analysis of Motor outcomes. J Clin Med. 2023;12(8):2846.","journal-title":"J Clin Med"},{"issue":"2","key":"3857_CR63","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1002\/mds.10024","volume":"17","author":"CG Goetz","year":"2002","unstructured":"Goetz CG, Leurgans S, Raman R. Placebo-associated improvements in motor function: comparison of subjective and objective sections of the UPDRS in early Parkinson\u2019s disease. Mov Disord. 2002;17(2):283\u20138.","journal-title":"Mov Disord"},{"issue":"5","key":"3857_CR64","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1002\/mds.21894","volume":"23","author":"CG Goetz","year":"2008","unstructured":"Goetz CG, Wuu J, McDermott MP, Adler CH, Fahn S, Freed CR, et al. Placebo response in Parkinson\u2019s disease: comparisons among 11 trials covering medical and surgical interventions. Mov Disord. 2008;23(5):690\u20139.","journal-title":"Mov Disord"},{"issue":"4","key":"3857_CR65","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1038\/s41591-024-02886-y","volume":"30","author":"G Pagano","year":"2024","unstructured":"Pagano G, Taylor KI, Anzures Cabrera J, Simuni T, Marek K, Postuma RB, et al. Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson\u2019s disease. Nat Med. 2024;30(4):1096\u2013103.","journal-title":"Nat Med"},{"issue":"4","key":"3857_CR66","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41582-019-0145-9","volume":"15","author":"P Limousin","year":"2019","unstructured":"Limousin P, Foltynie T. Long-term outcomes of deep brain stimulation in Parkinson disease. Nat Reviews Neurol. 2019;15(4):234\u201342.","journal-title":"Nat Reviews Neurol"},{"issue":"4","key":"3857_CR67","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nrneurol.2017.27","volume":"13","author":"D Aarsland","year":"2017","unstructured":"Aarsland D, Creese B, Politis M, Chaudhuri KR, ffytche DH, Weintraub D, et al. Cognitive decline in Parkinson disease. Nat Reviews Neurol. 2017;13(4):217\u201331.","journal-title":"Nat Reviews Neurol"},{"issue":"8","key":"3857_CR68","doi-asserted-by":"publisher","first-page":"e859","DOI":"10.1212\/WNL.0000000000013218","volume":"98","author":"K Tsukita","year":"2022","unstructured":"Tsukita K, Sakamaki-Tsukita H, Takahashi R. Long-term effect of regular physical activity and Exercise habits in patients with early Parkinson Disease. Neurology. 2022;98(8):e859\u201371.","journal-title":"Neurology"},{"issue":"n\/a","key":"3857_CR69","first-page":"1","volume":"n\/a","author":"C Tucak","year":"2023","unstructured":"Tucak C, Chih H, Mastaglia F, Rodrigues J. The \u2018PD Warrior\u2019 exercise program improves motor outcomes and quality of life in patients with early Parkinson\u2019s disease: results of a pilot study. Intern Med J. 2023;n\/a(n\/a):1\u201310.","journal-title":"Intern Med J"},{"issue":"4","key":"3857_CR70","doi-asserted-by":"publisher","first-page":"703","DOI":"10.3233\/JPD-171173","volume":"7","author":"M Afshari","year":"2017","unstructured":"Afshari M, Yang A, Bega D. Motivators and barriers to Exercise in Parkinson\u2019s Disease. J Parkinsons Dis. 2017;7(4):703\u201311.","journal-title":"J Parkinsons Dis"},{"issue":"4","key":"3857_CR71","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.3233\/JPD-202247","volume":"10","author":"S Schootemeijer","year":"2020","unstructured":"Schootemeijer S, Van Der Kolk NM, Ellis T, Mirelman A, Nieuwboer A, Nieuwhof F, et al. Barriers and motivators to engage in exercise for persons with Parkinson\u2019s disease. J Parkinson\u2019s Disease. 2020;10(4):1293\u20139.","journal-title":"J Parkinson\u2019s Disease"},{"issue":"11","key":"3857_CR72","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1007\/s40279-022-01714-y","volume":"52","author":"YM Dutra","year":"2022","unstructured":"Dutra YM, Malta ES, Elias AS, Broatch JR, Zagatto AM. Deconstructing the ergogenic effects of photobiomodulation: a systematic review and meta-analysis of its efficacy in improving mode-specific exercise performance in humans. Sports Med. 2022;52(11):2733\u201357.","journal-title":"Sports Med"},{"issue":"2","key":"3857_CR73","doi-asserted-by":"publisher","first-page":"282","DOI":"10.23736\/S1973-9087.21.07236-1","volume":"58","author":"MF De Oliveira","year":"2022","unstructured":"De Oliveira MF, Johnson DS, Demchak T, Tomazoni SS, Ernesto C. Low-intensity LASER and LED (photobiomodulation therapy) for pain control of the most common musculoskeletal conditions. Eur J Phys Rehabil Med. 2022;58(2):282.","journal-title":"Eur J Phys Rehabil Med"},{"issue":"15","key":"3857_CR74","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1002\/mds.22340","volume":"23","author":"CG Goetz","year":"2008","unstructured":"Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, et al. Movement Disorder Society\u2010sponsored revision of the Unified Parkinson\u2019s Disease Rating Scale (MDS\u2010UPDRS): scale presentation and clinimetric testing results. Mov Disorders: Official J Mov Disorder Soc. 2008;23(15):2129\u201370.","journal-title":"Mov Disorders: Official J Mov Disorder Soc"},{"key":"3857_CR75","doi-asserted-by":"publisher","first-page":"102745","DOI":"10.1016\/j.nicl.2021.102745","volume":"31","author":"C Charroud","year":"2021","unstructured":"Charroud C, Turella L. Subcortical grey matter changes associated with motor symptoms evaluated by the Unified Parkinson\u2019s disease rating scale (part III): a longitudinal study in Parkinson\u2019s disease. NeuroImage: Clin. 2021;31:102745.","journal-title":"NeuroImage: Clin"},{"issue":"7","key":"3857_CR76","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1002\/mds.21429","volume":"22","author":"A Schrag","year":"2007","unstructured":"Schrag A, Dodel R, Spottke A, Bornschein B, Siebert U, Quinn NP. Rate of clinical progression in Parkinson\u2019s disease. A prospective study. Mov Disord. 2007;22(7):938\u201345.","journal-title":"Mov Disord"},{"issue":"12","key":"3857_CR77","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1136\/jnnp-2018-318337","volume":"89","author":"M Lawton","year":"2018","unstructured":"Lawton M, Ben-Shlomo Y, May MT, Baig F, Barber TR, Klein JC, et al. Developing and validating Parkinson\u2019s disease subtypes and their motor and cognitive progression. J Neurol Neurosurg Psychiatry. 2018;89(12):1279\u201387.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"9","key":"3857_CR78","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1212\/01.wnl.0000183359.50822.f2","volume":"65","author":"G Alves","year":"2005","unstructured":"Alves G, Wentzel-Larsen T, Aarsland D, Larsen JP. Progression of motor impairment and disability in Parkinson disease. Neurology. 2005;65(9):1436\u201341.","journal-title":"Neurology"},{"issue":"1","key":"3857_CR79","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/mds.27492","volume":"34","author":"B Mollenhauer","year":"2019","unstructured":"Mollenhauer B, Zimmermann J, Sixel-D\u00f6ring F, Focke NK, Wicke T, Ebentheuer J, et al. Baseline predictors for progression 4 years after Parkinson\u2019s disease diagnosis in the De Novo Parkinson Cohort (DeNoPa). Mov Disord. 2019;34(1):67\u201377.","journal-title":"Mov Disord"},{"issue":"1","key":"3857_CR80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s41983-022-00445-1","volume":"58","author":"A Helmy","year":"2022","unstructured":"Helmy A, Hamid E, Salama M, Gaber A, El-Belkimy M, Shalash A. Baseline predictors of progression of Parkinson\u2019s disease in a sample of Egyptian patients: clinical and biochemical. Egypt J Neurol Psychiatry Neurosurg. 2022;58(1):1\u201310.","journal-title":"Egypt J Neurol Psychiatry Neurosurg"},{"issue":"10","key":"3857_CR81","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1001\/archneur.58.10.1611","volume":"58","author":"J Jankovic","year":"2001","unstructured":"Jankovic J, Kapadia AS. Functional decline in Parkinson disease. Arch Neurol. 2001;58(10):1611\u20135.","journal-title":"Arch Neurol"},{"key":"3857_CR82","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.parkreldis.2016.05.015","volume":"29","author":"A Merola","year":"2016","unstructured":"Merola A, Espay AJ, Romagnolo A, Bernardini A, Rizzi L, Rosso M, et al. Advanced therapies in Parkinson\u2019s disease: long-term retrospective study. Parkinsonism Relat Disord. 2016;29:104\u20138.","journal-title":"Parkinsonism Relat Disord"},{"key":"3857_CR83","doi-asserted-by":"publisher","first-page":"548","DOI":"10.3389\/fneur.2020.00548","volume":"11","author":"K Markopoulou","year":"2020","unstructured":"Markopoulou K, Aasly J, Chung SJ, Dardiotis E, Wirdefeldt K, Premkumar AP, et al. Longitudinal monitoring of Parkinson\u2019s disease in different ethnic cohorts: the DodoNA and LONG-PD study. Front Neurol. 2020;11:548.","journal-title":"Front Neurol"},{"key":"3857_CR84","doi-asserted-by":"publisher","first-page":"437","DOI":"10.3233\/JPD-212860","volume":"12","author":"M Bartl","year":"2022","unstructured":"Bartl M, Dakna M, Schade S, Wicke T, Lang E, Ebentheuer J, et al. Longitudinal change and progression indicators using the Movement Disorder Society-Unified Parkinson\u2019s Disease Rating Scale in two independent cohorts with early Parkinson\u2019s Disease. J Parkinson\u2019s Disease. 2022;12:437\u201352.","journal-title":"J Parkinson\u2019s Disease"},{"issue":"5","key":"3857_CR85","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1002\/mds.26960","volume":"32","author":"K Horv\u00e1th","year":"2017","unstructured":"Horv\u00e1th K, Aschermann Z, Kov\u00e1cs M, Makkos A, Harmat M, Janszky J, et al. Minimal clinically important differences for the experiences of daily living parts of movement disorder society\u2013sponsored unified Parkinson\u2019s disease rating scale. Mov Disord. 2017;32(5):789\u201393.","journal-title":"Mov Disord"},{"issue":"11","key":"3857_CR86","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1007\/s004150170047","volume":"248","author":"BR Bloem","year":"2001","unstructured":"Bloem BR, Grimbergen YAM, Cramer M, Willemsen M, Zwinderman AH. Prospective assessment of falls in Parkinson\u2019s disease. J Neurol. 2001;248(11):950\u20138.","journal-title":"J Neurol"},{"key":"3857_CR87","doi-asserted-by":"crossref","unstructured":"Allen NE, Schwarzel AK, Canning CG. Recurrent falls in Parkinson\u2019s disease: a systematic review. Parkinson\u2019s disease. 2013;2013.","DOI":"10.1155\/2013\/906274"},{"issue":"2","key":"3857_CR88","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1093\/ptj\/81.2.810","volume":"81","author":"S Morris","year":"2001","unstructured":"Morris S, Morris ME, Iansek R. Reliability of measurements obtained with the timed up & go test in people with Parkinson disease. Phys Ther. 2001;81(2):810\u20138.","journal-title":"Phys Ther"},{"issue":"12","key":"3857_CR89","doi-asserted-by":"publisher","first-page":"3675","DOI":"10.1589\/jpts.27.3675","volume":"27","author":"N Paker","year":"2015","unstructured":"Paker N, Bugdayci D, Goksenoglu G, Demircio\u011flu DT, Kesiktas N, Ince N. Gait speed and related factors in Parkinson\u2019s disease. J Phys Therapy Sci. 2015;27(12):3675\u20139.","journal-title":"J Phys Therapy Sci"},{"issue":"3","key":"3857_CR90","doi-asserted-by":"publisher","first-page":"247","DOI":"10.3233\/NRE-2011-0700","volume":"29","author":"M Bryant","year":"2011","unstructured":"Bryant M, Rintala D, Hou J, Lai E, Protas E. Effects of levodopa on forward and backward gait patterns in persons with Parkinson\u2019s disease. NeuroRehabilitation. 2011;29(3):247\u201352.","journal-title":"NeuroRehabilitation"},{"issue":"3","key":"3857_CR91","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1002\/mds.26110","volume":"30","author":"B Galna","year":"2015","unstructured":"Galna B, Lord S, Burn DJ, Rochester L. Progression of gait dysfunction in incident Parkinson\u2019s disease: impact of medication and phenotype. Mov Disord. 2015;30(3):359\u201367.","journal-title":"Mov Disord"},{"issue":"16","key":"3857_CR92","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1212\/WNL.0000000000003840","volume":"88","author":"L Rochester","year":"2017","unstructured":"Rochester L, Galna B, Lord S, Yarnall AJ, Morris R, Duncan G, et al. Decrease in A\u03b242 predicts dopa-resistant gait progression in early Parkinson disease. Neurology. 2017;88(16):1501\u201311.","journal-title":"Neurology"},{"issue":"8","key":"3857_CR93","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.2522\/ptj.20140498","volume":"95","author":"JT Cavanaugh","year":"2015","unstructured":"Cavanaugh JT, Ellis TD, Earhart GM, Ford MP, Foreman KB, Dibble LE. Toward understanding ambulatory activity decline in Parkinson disease. Phys Ther. 2015;95(8):1142\u201350.","journal-title":"Phys Ther"},{"key":"3857_CR94","doi-asserted-by":"publisher","first-page":"577435","DOI":"10.3389\/fnagi.2020.577435","volume":"12","author":"J Wilson","year":"2020","unstructured":"Wilson J, Alcock L, Yarnall AJ, Lord S, Lawson RA, Morris R, et al. Gait Progression over 6 years in Parkinson\u2019s Disease: effects of Age, Medication, and Pathology. Front Aging Neurosci. 2020;12:577435.","journal-title":"Front Aging Neurosci"},{"issue":"6","key":"3857_CR95","doi-asserted-by":"publisher","first-page":"733","DOI":"10.2522\/ptj.20070214","volume":"88","author":"T Steffen","year":"2008","unstructured":"Steffen T, Seney M. Test-retest reliability and minimal detectable change on balance and ambulation tests, the 36-item short-form health survey, and the unified Parkinson disease rating scale in people with parkinsonism. Phys Ther. 2008;88(6):733\u201346.","journal-title":"Phys Ther"},{"issue":"4","key":"3857_CR96","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1097\/NPT.0000000000000055","volume":"38","author":"CJ Hass","year":"2014","unstructured":"Hass CJ, Bishop M, Moscovich M, Stegem\u00f6ller EL, Skinner J, Malaty IA, et al. Defining the clinically meaningful difference in gait speed in persons with Parkinson disease. J Neurol Phys Ther. 2014;38(4):233\u20138.","journal-title":"J Neurol Phys Ther"},{"issue":"10","key":"3857_CR97","first-page":"jrm00234","volume":"53","author":"S Sebastia-Amat","year":"2021","unstructured":"Sebastia-Amat S, Tortosa-Mart\u00ednez J, Garc\u00eda-Ja\u00e9n M, Pueo B. Within-subject variation in the cognitive timed up and go test as an explanatory variable in fall risk in patients with parkinson\u2019s disease. J Rehabil Med. 2021;53(10):jrm00234.","journal-title":"J Rehabil Med"},{"key":"3857_CR98","doi-asserted-by":"crossref","unstructured":"\u00c7ekok K, Kahraman T, Duran G, \u00c7olako\u011flu BD, Yener G, Yerlikaya D et al. Timed up and go Test with a Cognitive Task: correlations with neuropsychological measures in people with Parkinson\u2019s Disease. Cureus. 2020;12(9).","DOI":"10.7759\/cureus.10604"},{"issue":"7","key":"3857_CR99","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1016\/j.apmr.2013.02.020","volume":"94","author":"JR Nocera","year":"2013","unstructured":"Nocera JR, Stegem\u00f6ller EL, Malaty IA, Okun MS, Marsiske M, Hass CJ. Using the timed up & go test in a clinical setting to predict falling in Parkinson\u2019s disease. Arch Phys Med Rehabil. 2013;94(7):1300\u20135.","journal-title":"Arch Phys Med Rehabil"},{"issue":"1","key":"3857_CR100","doi-asserted-by":"publisher","first-page":"114","DOI":"10.2522\/ptj.20090126","volume":"91","author":"S-L Huang","year":"2011","unstructured":"Huang S-L, Hsieh C-L, Wu R-M, Tai C-H, Lin C-H, Lu W-S. Minimal detectable change of the timed Up & Go Test and the dynamic Gait Index in People with Parkinson Disease. Phys Ther. 2011;91(1):114\u201321.","journal-title":"Phys Ther"},{"issue":"1","key":"3857_CR101","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s11357-022-00606-3","volume":"45","author":"YA Chen","year":"2023","unstructured":"Chen YA, Wu RM, Sheu CH, Lin CH, Huang CY. Attentional focus effect on dual-task walking in Parkinson\u2019s disease with and without freezing of gait. Geroscience. 2023;45(1):177\u201395.","journal-title":"Geroscience"},{"issue":"2","key":"3857_CR102","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1590\/bjpt-rbf.2014.0082","volume":"19","author":"LC Lima","year":"2015","unstructured":"Lima LC, Ansai JH, Andrade LP, Takahashi AC. The relationship between dual-task and cognitive performance among elderly participants who exercise regularly. Braz J Phys Ther. 2015;19(2):159\u201366.","journal-title":"Braz J Phys Ther"},{"issue":"12","key":"3857_CR103","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1177\/0269215519877498","volume":"33","author":"SJ Winser","year":"2019","unstructured":"Winser SJ, Kannan P, Bello UM, Whitney SL. Measures of balance and falls risk prediction in people with Parkinson\u2019s disease: a systematic review of psychometric properties. Clin Rehabil. 2019;33(12):1949\u201362.","journal-title":"Clin Rehabil"},{"key":"3857_CR104","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12938-020-00776-1","volume":"19","author":"Z Rahmati","year":"2020","unstructured":"Rahmati Z, Behzadipour S, Schouten AC, Taghizadeh G, Firoozbakhsh K. Postural control learning dynamics in Parkinson\u2019s disease: early improvement with plateau in stability, and continuous progression in flexibility and mobility. Biomed Eng Online. 2020;19:1\u201322.","journal-title":"Biomed Eng Online"},{"key":"3857_CR105","doi-asserted-by":"publisher","first-page":"205520761988557","DOI":"10.1177\/2055207619885573","volume":"5","author":"C Zhang","year":"2019","unstructured":"Zhang C, Talaber A, Truong M, Vargas BB. K-D balance: an objective measure of balance in tandem and double leg stances. Digit Health. 2019;5:2055207619885573.","journal-title":"Digit Health"},{"issue":"8","key":"3857_CR106","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1097\/MAO.0b013e31822e5bee","volume":"32","author":"Y Agrawal","year":"2011","unstructured":"Agrawal Y, Carey JP, Hoffman HJ, Sklare DA, Schubert MC. The modified Romberg Balance Test: normative data in U.S. adults. Otol Neurotol. 2011;32(8):1309\u201311.","journal-title":"Otol Neurotol"},{"issue":"1","key":"3857_CR107","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1519\/00139143-200704000-00003","volume":"30","author":"BA Springer","year":"2007","unstructured":"Springer BA, Marin R, Cyhan T, Roberts H, Gill NW. Normative values for the unipedal stance test with eyes open and closed. J Geriatr Phys Ther. 2007;30(1):8\u201315.","journal-title":"J Geriatr Phys Ther"},{"issue":"10","key":"3857_CR108","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1016\/j.parkreldis.2015.08.024","volume":"21","author":"G Santangelo","year":"2015","unstructured":"Santangelo G, Vitale C, Picillo M, Moccia M, Cuoco S, Longo K, et al. Mild cognitive impairment in newly diagnosed Parkinson\u2019s disease: a longitudinal prospective study. Parkinsonism Relat Disord. 2015;21(10):1219\u201326.","journal-title":"Parkinsonism Relat Disord"},{"issue":"3","key":"3857_CR109","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1001\/archneur.60.3.387","volume":"60","author":"D Aarsland","year":"2003","unstructured":"Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-S\u00f8rensen P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol. 2003;60(3):387\u201392.","journal-title":"Arch Neurol"},{"issue":"2","key":"3857_CR110","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3233\/JPD-181306","volume":"8","author":"M Roheger","year":"2018","unstructured":"Roheger M, Kalbe E, Liepelt-Scarfone I. Progression of cognitive decline in Parkinson\u2019s disease. J Parkinson\u2019s Disease. 2018;8(2):183\u201393.","journal-title":"J Parkinson\u2019s Disease"},{"key":"3857_CR111","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.parkreldis.2016.10.005","volume":"33","author":"A-MA Wills","year":"2016","unstructured":"Wills A-MA, Elm JJ, Ye R, Chou KL, Parashos SA, Hauser RA, et al. Cognitive function in 1736 participants in NINDS exploratory trials in PD Long-term Study-1. Parkinsonism Relat Disord. 2016;33:127\u201333.","journal-title":"Parkinsonism Relat Disord"},{"issue":"6","key":"3857_CR112","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1017\/S1355617713000295","volume":"19","author":"M Broeders","year":"2013","unstructured":"Broeders M, Velseboer DC, de Bie R, Speelman JD, Muslimovic D, Post B, et al. Cognitive change in newly-diagnosed patients with Parkinson\u2019s disease: a 5-year follow-up study. J Int Neuropsychol Soc. 2013;19(6):695\u2013708.","journal-title":"J Int Neuropsychol Soc"},{"issue":"12","key":"3857_CR113","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1001\/archneur.61.12.1906","volume":"61","author":"D Aarsland","year":"2004","unstructured":"Aarsland D, Andersen K, Larsen JP, Perry R, Wentzel-Larsen T, Lolk A, et al. The rate of Cognitive decline in Parkinson Disease. Arch Neurol. 2004;61(12):1906\u201311.","journal-title":"Arch Neurol"},{"key":"3857_CR114","doi-asserted-by":"crossref","unstructured":"Greenland JC, Camacho M, Williams-Gray CH. Chapter 12 - The dilemma between milestones of progression versus clinical scales in Parkinson\u2019s disease. In: Espay AJ, editor. Handbook of clinical neurology. Volume 192. Elsevier; 2023. pp. 169\u201385.","DOI":"10.1016\/B978-0-323-85538-9.00010-9"},{"issue":"6","key":"3857_CR115","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1177\/1073191116654217","volume":"24","author":"K Krishnan","year":"2017","unstructured":"Krishnan K, Rossetti H, Hynan LS, Carter K, Falkowski J, Lacritz L, et al. Changes in Montreal Cognitive Assessment scores over time. Assessment. 2017;24(6):772\u20137.","journal-title":"Assessment"},{"issue":"6","key":"3857_CR116","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1001\/jamaneurol.2014.391","volume":"71","author":"SA Parashos","year":"2014","unstructured":"Parashos SA, Luo S, Biglan KM, Bodis-Wollner I, He B, Liang GS, et al. Measuring disease progression in early Parkinson disease: the National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) experience. JAMA Neurol. 2014;71(6):710\u20136.","journal-title":"JAMA Neurol"},{"key":"3857_CR117","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.parkreldis.2018.06.034","volume":"56","author":"A Margolius","year":"2018","unstructured":"Margolius A, Cubillos F, He Y, Wu S, Schmidt P, Simuni T. Predictors of clinically meaningful change in PDQ-39 in Parkinson\u2019s disease. Parkinsonism Relat Disord. 2018;56:93\u20137.","journal-title":"Parkinsonism Relat Disord"},{"issue":"1\u20132","key":"3857_CR118","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000455863","volume":"48","author":"K Horv\u00e1th","year":"2017","unstructured":"Horv\u00e1th K, Aschermann Z, Kov\u00e1cs M, Makkos A, Harmat M, Janszky J, et al. Changes in quality of life in Parkinson\u2019s Disease: how large must they be to be relevant? Neuroepidemiology. 2017;48(1\u20132):1\u20138.","journal-title":"Neuroepidemiology"},{"issue":"1","key":"3857_CR119","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41531-018-0053-5","volume":"4","author":"S Kharkar","year":"2018","unstructured":"Kharkar S, Ellenbogen JR, Samuel M, Rizos A, Silverdale M, Chaudhuri KR, et al. Changes in Parkinson\u2019s disease sleep symptoms and daytime somnolence after bilateral subthalamic deep brain stimulation in Parkinson\u2019s disease. Npj Parkinson\u2019s Disease. 2018;4(1):16.","journal-title":"Npj Parkinson\u2019s Disease"},{"key":"3857_CR120","doi-asserted-by":"publisher","first-page":"101416","DOI":"10.1016\/j.arr.2021.101416","volume":"70","author":"X Dan","year":"2021","unstructured":"Dan X, Wechter N, Gray S, Mohanty JG, Croteau DL, Bohr VA. Olfactory dysfunction in aging and neurodegenerative diseases. Ageing Res Rev. 2021;70:101416.","journal-title":"Ageing Res Rev"},{"issue":"7","key":"3857_CR121","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1002\/mdc3.13028","volume":"7","author":"S Sasaki","year":"2020","unstructured":"Sasaki S, Horie Y. Association between Olfactory Impairment and Disease Severity and Duration in Parkinson\u2019s Disease. Mov Disorders Clin Pract. 2020;7(7):820\u20136.","journal-title":"Mov Disorders Clin Pract"},{"issue":"3","key":"3857_CR122","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.anl.2020.11.020","volume":"48","author":"H Suzuki","year":"2021","unstructured":"Suzuki H, Teranishi M, Katayama N, Nakashima T, Sugiura S, Sone M. Relationship between cognitive impairment and olfactory function among older adults with olfactory impairment. Auris Nasus Larynx. 2021;48(3):420\u20137.","journal-title":"Auris Nasus Larynx"},{"key":"3857_CR123","doi-asserted-by":"crossref","unstructured":"Tarakad A, Jankovic J. Chapter Seventeen - Anosmia and Ageusia in Parkinson\u2019s Disease. In: Chaudhuri KR, Titova N, editors. International Review of Neurobiology. Volume 133. Academic; 2017. pp. 541\u201356.","DOI":"10.1016\/bs.irn.2017.05.028"},{"issue":"2","key":"3857_CR124","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1089\/photob.2021.0056","volume":"40","author":"A Liebert","year":"2022","unstructured":"Liebert A, Bicknell B, Laakso E-L, Jalilitabaei P, Tilley S, Kiat H, et al. Remote Photobiomodulation treatment for the clinical signs of Parkinson\u2019s Disease: a Case Series Conducted during COVID-19. Photobiomodulation Photomed Laser Surg. 2022;40(2):112\u201322.","journal-title":"Photobiomodulation Photomed Laser Surg"},{"key":"3857_CR125","doi-asserted-by":"crossref","unstructured":"Liebert A, Saltmarche A, McGonaghy M, Hares O, Bicknell B, Herkes G. Photobiomodulation as part of a multi-disciplinary approach for the treatment of Parkinson\u2019s disease symptoms. Medical Research Archives. 2024;in press.","DOI":"10.18103\/mra.v12i9.5648"},{"key":"3857_CR126","doi-asserted-by":"crossref","unstructured":"Salehpour F, Hamblin MR, DiDuro JO. Rapid reversal of cognitive decline, olfactory dysfunction, and quality of life using multi-modality photobiomodulation therapy: case report. Photobiomodulation, photomedicine, and laser surgery. 2019;37(3):159\u201367.","DOI":"10.1089\/photob.2018.4569"},{"key":"3857_CR127","doi-asserted-by":"crossref","unstructured":"Hamilton C, Hamilton D, Nicklason F, Mitrofanis J. Transcranial photobiomodulation therapy: observations from four movement disorder patients. In: Caldieraro M, Cassano P, editors. Photobiomodulation in the Brain: Elsevier; 2019. pp. 463\u2009\u2013\u200972.","DOI":"10.1016\/B978-0-12-815305-5.00033-6"},{"issue":"6","key":"3857_CR128","doi-asserted-by":"publisher","first-page":"e202300003","DOI":"10.1002\/jbio.202300003","volume":"16","author":"VH Panhoca","year":"2023","unstructured":"Panhoca VH, Ferreira LT, de Souza VB, Ferreira SA, Sim\u00e3o G, de Aquino Junior AE, et al. Can photobiomodulation restore anosmia and ageusia induced by COVID-19? A pilot clinical study. J Biophotonics. 2023;16(6):e202300003.","journal-title":"J Biophotonics"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-024-03857-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-024-03857-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-024-03857-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T13:04:45Z","timestamp":1728479085000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-024-03857-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,9]]},"references-count":128,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3857"],"URL":"https:\/\/doi.org\/10.1186\/s12883-024-03857-z","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,9]]},"assertion":[{"value":"31 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study received human research ethics approval by the Griffith University Human Research Ethics Committee (2018\/16), with an extension to 24th April 2024. All participants gave written informed consent prior to taking part in the study. All protocols were approved by the Griffith University Human Research Ethics Committee and were conducted in accordance with their regulations and guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AL and BB are co-founders, and shareholders in SYMBYX Pty Ltd, a med-tech company developing photobiomodulation treatments for neurological disorders. HK and ELL are shareholders in SYMBYX Pty Ltd.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"381"}}